Clinical decision support
Also, Lunit has received Taiwan's approval for its AI mammography solution.
The AI model still has a modest prediction accuracy and is slated for a wider clinical trial soon.
It will use its fresh funds to complete a multi-site validation study across eight Asia-Pacific markets.
Formerly known as IDx, the company received FDA De Novo clearance in 2018 for its IDx-DR system used to detect diabetic retinopathy.
It measures the cortical thickness in a brain scan to provide a patient's level of brain ageing.
Also, a new online repository of health and wellness knowledge has been launched in India.
![[Left] Ed Deng, co-founder and CEO, Health2Sync; and [Right] Claudio Longo, President, AstraZeneca Taiwan](/sites/mhn/files/styles/230x130/public/2025-07/%2528Left%2529%2520Ed%2520Deng%252C%2520Co-founder%2520and%2520CEO%2520of%2520Health2Sync%2520and%2520%2528Right%2529%2520Claudio%2520Longo%252C%2520President%2520of%2520AstraZeneca%2520Taiwan.jpg?itok=XO7M1UnC)
Health2Sync has upgraded its patient management platform to identify patients' CKD risk levels.
Also, annalise.ai has made key executive appointments to support its global expansion.
They have so far developed AI prediction models for breast, colon, and lung cancers.
It will be the first integration of Lunit's AI radiology software into an insurance underwriting workflow.